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We investigated prognostic factors for the clinical outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in
patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (PhþALL) following imatinib-based therapy.
Among 100 adult patients who were prospectively enrolled in the JALSG PhþALL202 study, 97 patients obtained complete
remission (CR) by imatinib-combined chemotherapy, among whom 60 underwent allo-HSCT in their ﬁrst CR. The probabilities of
overall survival (OS) and disease-free survival (DFS) at 3 years after HSCT were 64% (95% CI, 49–76) and 58% (95% CI, 43–70),
respectively. Prognostic factor analysis revealed that the major BCR–ABL transcript was the only unfavorable predictor for OS and
DFS after HSCT by both univariate (HR, 3.67 (95% CI 1.49–9.08); P¼0.005 and HR, 6.25 (95% CI, 1.88–20.8); P¼0.003, respectively)
and multivariate analyses (HR, 3.20 (95% CI, 1.21–8.50); P¼0.019 and HR, 6.92 (95% CI, 2.09–22.9); P¼0.002, respectively). Minimal
residual disease status at the time of HSCT had a signiﬁcant inﬂuence on relapse rate (P¼0.015). Further study of the BCR–ABL
subtype for the clinical impact on outcome of allo-HSCT in PhþALL is warranted.
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INTRODUCTION
Approximately 20 to 25% of adult patients with acute lympho-
blastic leukemia (ALL) harbor BCR–ABL fusion gene. The prognosis
following conventional chemotherapy of these patients had
been extremely poor.
1–3 Although the treatment of Philadelphia
chromosome-positive ALL (PhþALL) has been changed
dramatically since the introduction of imatinib,
4 allogeneic
hematopoietic stem cell transplantation (allo-HSCT) still seems to
have a central role as a curative option for patients with PhþALL
in the imatinib era.
5–7 Previously we reported that the patients
who had achieved complete remission (CR) by imatinib-based
therapy, and subsequently received allo-HSCT in their ﬁrst CR,
showed signiﬁcantly superior survival to those patients in the
pre-imatinib era.
8 Imatinib-based therapy is a useful strategy,
giving patients not only a better chance to receive allo-HSCT but
also improvement of the outcome after allo-HSCT. However, the
treatment success after allo-HSCT is impaired by the occurrence
of post-transplant relapse and non-relapse mortality (NRM),
9–11
and therefore, identiﬁcation of the risk factors causing relapse and
NRM after allo-HSCT would be beneﬁcial.
In the present study, we evaluated prognostic factors inﬂuen-
cing overall survival (OS), disease-free survival (DFS), relapse
and NRM after allo-HSCT among patients with PhþALL who
underwent HSCT in the imatinib era, by using the prospectively
conducted data of Japan Adult Leukemia Study Group (JALSG)
PhþALL202 study.
PATIENTS AND METHODS
Patients
In the JALSG PhþALL202 study, 100 newly diagnosed patients with BCR–
ABL-positive ALL were registered consecutively between September 2002
and May 2005. All patients were diagnosed as PhþALL by real-time
quantitative PCR (RQ-PCR) analysis, and received the same imatinib-
combined chemotherapy, as described previously.
12 Of 97 patients who
achieved CR, 60 patients received allo-HSCT in their ﬁrst CR. Table 1 shows
the characteristics of these 60 patients analyzed in the present study.
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www.nature.com/bcjIn the PhþALL202 study, allo-HSCT was recommended after achieving CR
if a human leukocyte antigen (HLA)-identical donor was available. The
stem-cell source for allo-HSCT was chosen in the following order: ﬁrst,
matched related donor; second, HLA-A, B and DRB1 allele matched (6/6) or
DRB1 one-allele mismatched unrelated donor; and third, unrelated cord
blood or HLA-mismatched related donor. Timing and procedure of HSCT,
including conditioning regimen and graft-versus-host disease (GVHD)
prophylaxis, were determined by each institution.
Among 60 patients, 32 were males and 28 females, with a median age of
37 years (range, 15–64 years), while 33 patients were less than 40.
Regarding the BCR–ABL transcript types, two patients expressed both
major and minor BCR–ABLs, and were categorized into the major BCR–ABL
group in the subsequent analysis. Consequently, 42 patients were positive
for minor BCR–ABL and 18 for major BCR–ABL. Pre-treatment cytogenetic
results were not available for four patients because no analysis was
performed (n¼2) nor successful (n¼2). Of the remaining 56 patients,
10 showed only t(9;22), 44 showed additional chromosome aberrations
and 2 showed normal karyotype. Additional aberrations were comprised of
þder (22) t(9;22) in 12 patients, del(9) in 3, monosomy 7 in 6 and trisomy
8 in 6. The study was approved by the institutional review board of each
participating center and conducted in accordance with the Declaration of
Helsinki.
Quantiﬁcation of BCR–ABL Transcripts
The copy number of BCR–ABL transcripts in bone marrow was determined
at the central laboratory using the RQ-PCR as described previously.
12 To
minimize the variability owing to differences in the efﬁciency of cDNA
synthesis and RNA integrity among patient samples, the copy numbers of
BCR–ABL transcripts were converted to molecules per microgram RNA after
being normalized by GAPDH. The normalized values of the BCR–ABL copies
in each sample were reported as the BCR–ABL number of copies. At least
5.7 10
5 copies/mg RNA GAPDH levels were required in a sample to be
deﬁned as a negative PCR result; otherwise, the sample was not used for
minimal residual disease (MRD) studies. The threshold for quantiﬁcation
was 50 copies/mg RNA, which corresponded to a minimal sensitivity of
10
 5. The levels below this threshold were designated as ‘not detected’ or
‘less than 50 copies/mg’, and the former was categorized as PCR negativity.
MRD at the time of HSCT was evaluated by the result of RQ-PCR within
30 days before respective transplantation.
Statistical Considerations
The aim of this study was to identify prognostic factors for clinical outcome
after allo-HSCT in patients with PhþALL transplanted in their CR in the
imatinib era. Primary endpoint was OS after allo-HSCT, and secondary
endpoints were NRM, relapse and DFS. OS was calculated from the date of
transplantation to the date of death by any cause, or the last known date
of follow-up. DFS was computed from the date of transplantation to the
date of relapse, or death by any cause, or the last known date of follow-up.
The probabilities of OS and DFS were estimated by Kaplan–Meier product
limit method. Cumulative incidence of NRM, relapse, acute GVHD (aGVHD)
and chronic GVHD (cGVHD) were estimated by the method taking the
competing risks into account, as described elsewhere.
13 In each estimation
of cumulative incidence of events, death without an event was deﬁned as
a competing risk. Risk factors were evaluated by combination of uni- and
multivariate analyses. We applied for univariate analysis Cox regression
models or the log-rank test, and for multivariate analysis the Cox
proportional hazards regression model or the competing risk regression
model as appropriate.
14
Covariates considered in uni- and multivariate analyses were: donor
status, age at HSCT (o40, vs X40), CD20 positivity (yes vs no), WBC counts
at diagnosis (430 10
9/l vs o30 10
9/l), additional chromosomal
abnormality, stem-cell source (bone marrow, peripheral blood or cord
blood), conditioning regimen (myeloablative vs reduced intensity),
BCR–ABL subtype (major vs minor), performance status at HSCT (1–2 vs
0) and MRD at HSCT (PCR positive vs negative). Neutrophil recovery was
deﬁned by neutrophil counts of X0.5 10
9/l in three consecutive days.
Graft failure was deﬁned as no sign of neutrophil recovery. aGVHD and
cGVHD were deﬁned according to previously described standard criteria.
15
RESULTS
Transplantation
Graft and conditioning regimen characteristics are summarized in
Table 1. The median day from diagnosis to HSCT was 164 (range
67–512 days). One patient with no HLA-matched related donor
received the scheduled therapy until a HLA-matched unrelated
donor was available, and underwent HSCT at 512 days. The
majority of donors were HLA-matched related (n¼24) and
unrelated (n¼21), followed by mismatched unrelated cord blood
(n¼9) and mismatched related donors (n¼6). Patients were
Table 1. Patient characteristics (N¼60)
Characteristics No. of patients %
Donor status
Related 39 65
Unrelated 21 35
Age at HSCT (years)
–39 33 55
40– 27 45
BCR–ABL isoform
Minor 42 70
Major 18 30
Additional chromosome abnormality (4 subjects unknown)
No 10 17
Yes 44 83
WBC at diagnosis ( 10
9/l)
o30 34 57
X30 26 43
CD 20 positivity (9 subjects unknown)
Negative 28 47
Positive 23 38
Stem-cell source
Bone marrow 35 58
Peripheral blood 16 27
Cord blood 9 15
Conditioning regimen
Myeloablative 54 90
CY þ TBI 27 45
CY þ CA þ TBI 15 25
CY þ VP þ TBI 1 2
CY þ TESPA þ TBI 4 7
CY þ BU 3 5
Others 4 7
Reduced intensity 6 10
Flu þ BU 3 5
Flu þ LPAM ± TBI 3 5
Performance status at HSCT
03 9 6 5
1–2 21 35
MRD status at HSCT (3 subjects unknown)
PCR negative 39 65
PCR positive 18 30
GVHD prophylaxis
Cyclosporine þ sMTX 31 52
Cyclosporine ± other 4 7
Tacrolimus þ sMTX 23 38
Others 2 3
Abbreviations: BU, busulfan (oral); CA, cytarabine; CY, cyclophosphamide;
Flu, fuludarabine; HSCT, hematopoietic stem-cell transplantation; LPAM,
melphalan; MRD, minimal residual disease; sMTX, short-term methotrexate;
TBI, total body irradiation; TESPA, tespamine; VP, etoposide; WBC, white
blood corpuscles.
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transplant centers. The majority of patients (70%) received
fractionated total body irradiation followed by cyclophosphamide
and/or cytarabine. Six patients, older than 55, were given a
reduced-intensity regimen consisting of ﬂudarabine and
melphalan or busulfan. No patient received imatinib therapy after
HSCT. All patients who showed hematological relapse after
HSCT received salvage treatment comprising of imatinib and/or
chemotherapy.
The median days to reach a neutrophil count 40.5 10
9/l and
platelet count X50 10
9/l were 15 (range: 5–41 days) and 27
(range: 11–504 days), respectively. Cumulative incidence of grade
2 to 4 of aGVHD and of cGVHD at 1 year after HSCT were 33.3%
(95% CI, 12–33%) and 44% (95% CI, 29–58%), respectively.
OS and DFS
With a median follow-up of 31 months (range, 12 to 56) after
HSCT, 41 patients were alive without relapse. The probability of OS
and DFS at 3 years after HSCT were 64% (95% CI; 49–76%) and
58% (95% CI; 43–70%), respectively (Figure 1). By the uni- and
multivariate analysis, the presence of major BCR–ABL transcript
was only associated with unfavorable OS (HR¼3.67 (95% CI,
1.49–9.08); P¼0.005, and HR¼6.25 (95% CI, 1.88–20.8); P¼0.003,
respectively) and DFS (HR¼2.60 (95% CI, 1.16–5.83); P¼0.02, and
HR¼3.20 (95% CI, 1.21–8.50); P¼0.019, respectively) (Table 2).
Figure 2 illustrates the 3-year OS and DFS in patients with major
and minor BCR–ABL subtypes (37% vs 75%; P¼0.003 and 33% vs
68%; P¼0.016, respectively).
Relapse
Overall, 9 patients (15%) relapsed after HSCT, with a median day of
167 (range, 68–728 days). The estimated cumulative incidence of
relapse at 3 years was 17% (95% CI, 8.3–28.0%). By the univariate
analysis for relapse, PCR-negativity at HSCT (HR¼4.82 (95% CI,
1.20–19.4); P¼0.027) and peripheral blood as a stem-cell source
(HR¼5.53 (95% CI, 1.06–29.0); P¼0.043) were associated with a
lower relapse rate, but they did not reach statistical signiﬁcance by
the multivariate analysis (HR¼7.34 (95% CI, 0.54–99.4); P¼0.134
and HR¼4.92 (95% CI, 0.17–144.0); P¼0.355, respectively)
(Table 3). The 3-year cumulative incidence of relapse rate was
not different in patients with major and minor BCR–ABL subtypes
(8% vs 20%; P¼0.34).
NRM
Nineteen patients died after HSCT: 6 from relapsed ALL and 13
from causes other than leukemia. The causes of NRM included
graft failure in 5, infection in 3, bronchiolitis obliterans in 2, cGVHD
in 2 and unknown in 1. Estimated cumulative incidences of NRM
at 3 years were 26% (95% CI, 14.8–38.7). By both uni- and
multivariate analyses, the presence of major BCR–ABL transcript
was associated with a higher NRM rate (HR¼5.95 (95% CI,
2.06–17.2); P¼0.001, and 6.92 (95% CI, 2.09–22.9), vs 0.002,
respectively) (Table 3).
Figure 2 illustrates the 3-year cumulative incidence of NRM in
patients with major and minor BCR–ABL subtypes (57% vs 13%;
P¼0.0004). Four patients (22%) with major BCR–ABL transcript,
but only one (2%) with minor transcript, died from graft failure
(Table 4).
DISCUSSION
In the present study, in patients with PhþALL who had achieved
CR by imatinib-based therapy and subsequently received
allo-HSCT in their ﬁrst CR, the major BCR–ABL subtype revealed
signiﬁcantly unfavorable prognostic impact on NRM, and conse-
quently on OS and DFS (Figure 2). During the pre-imatinib era,
several groups reported the relationship between the clinical
outcome and BCR–ABL subtypes in patients with PhþALL.
German Multicenter Adult ALL Study Group reported a trend
toward poor OS for patients with major BCR–ABL (19% OS for the
minor and 3% for the major at 3 years, P¼0.07).
2 Gruppo Italiano
Malattie Ematologiche dell’ Adulto also reported that minor BCR–
ABL was an independent prognostic factor favorably affecting the
5-year OS and DFS (P¼0.008 and P¼0.02, respectively), although
response rates to the induction therapy were similar in both
groups.
16 Of note in their study, none of 14 patients with major
BCR–ABL transcript who underwent HSCT (8 allogeneic and
6 autologous) survived in CR, whereas, among 22 patients with
minor BCR–ABL, 6 of 12 who received allo-HSCT and 2 of 10 who
received autologous HSCT survived in CR.
Figure 1. (a) OS and (b) DFS of 60 patients with PhþALL who underwent allo-HSCT in their ﬁrst CR following imatinib-based therapy.
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transcript showed signiﬁcantly unfavorable OS rates, compared
with those with minor BCR–ABL transcript. Among 100 patients
registered into the JALSG PhþALL 202 study, three patients died
from chemotherapy-related toxicity during induction therapy and
all of them expressed minor BCR–ABL transcript. Additionally,
among 40 patients who did not receive HSCT in their ﬁrst CR, OS
of 7 patients with major BCR–ABL transcript was not inferior to that
of 33 patients with minor BCR–ABL (P¼0.254) (Supplemental
ﬁgure S1). Therefore, the unfavorable clinical impact of major BCR–
ABL transcript might be speciﬁc in the setting of allo-HSCT. Then
the question arises: How the BCR–ABL subtype inﬂuenced the
prognosis after allo-HSCT?
As shown in Table 4, MRD status and the period from diagnosis
to HSCT were not signiﬁcantly different among patients with
major or minor BCR–ABL transcript. As the cause of NRM after
allo-HSCT, high incidence of graft failure (22%) was observed in
patients with major BCR–ABL (Table 4), and to predict NRM,
transplantation-speciﬁc comorbidity index (HCT-CI) is reportedly
useful.
17 In the present study, 54 of 60 patients could be evaluable
for this scoring system, but we found no difference in HCT-CI
scores between major and minor BCR–ABL subtypes (P¼0.40).
Biological heterogeneities between major and minor BCR–ABL
transcripts may have inﬂuenced NRM of HSCT. Juric et al.
18
performed a comprehensive analysis of the gene expression
proﬁles in 37 BCR–ABL-positive adult ALL. They identiﬁed the
genes overexpressed (PILRB, STS-1, SPRY1) or underexpressed
(TSPAN16, ADAMTSL4) in ALL with minor BCR–ABL transcript,
relative to ALL with major BCR–ABL, and constructed a gene
expression- and interaction-based outcome predictor, consisting
of 27 genes, which correlated with OS, independent of age and
WBC count at presentation. Zheng et al.
19 spotlighted the role of
the reciprocal ABL–BCR fusion proteins, derivative chromosome
9 (der 9) -associated p96
ABL–BCR and p40
ABL–BCR fusion proteins.
They indicated that p96
ABL–BCR and p40
ABL–BCR fusion proteins
regulated the different expression of genes involved in the
maintenance of stem-cell capacity. However, even if the biological
heterogeneity would affect the clinical outcome of patients,
Table 2. Uni- and multivariate analyses for OS and DFS of 60 patients who received HSCT in their ﬁrst CR following imatinib-based therapy
Characteristics OS DFS
Univariate Multivariate Univariate Multivariate
RR (95% CI) P RR (95% CI) P RR (95% CI) P RR (95% CI) P
Donor status
Related 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Unrelated 1.43 (0.57–3.57) 0.443 1.27 (0.24–6.64) 0.779 0.93 (0.40–2.17) 0.865 0.72 (0.15–3.59) 0.692
Age at HSCT (years)
–39 1 (reference) 1 (reference) 1 (reference) 1 (reference)
40– 1.55 (0.63–3.82) 0.339 3.04 (0.91–10.2) 0.072 1.09 (0.49–2.44) 0.833 1.22 (0.42–3.49) 0.715
Additional chromosome abnormality
a
No 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Yes 0.91 (0.26–3.20) 0.882 0.71 (0.17–3.02) 0.647 0.97 (0.33–2.89) 0.958 0.75 (0.21–2.72) 0.666
Stem-cell source
Bone marrow 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Peripheral blood 0.73 (0.24–2.28) 0.592 1.19 (0.23–6.20) 0.840 1.58 (0.64–3.87) 0.318 1.99 (0.48–8.15) 0.340
Cord blood 1.01 (0.28–3.57) 0.994 2.61 (0.37–18.4) 0.335 1.52 (0.49–4.72) 0.468 1.94 (0.32–11.8) 0.473
Conditioning regimen
Myeloablative 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Reduced intensity NE NE NE NE
BCR–ABL subtype
Minor 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Major 3.67 (1.49–9.08) 0.005 6.25 (1.88–20.8) 0.003 2.60 (1.16–5.83) 0.020 3.20 (1.21–8.50) 0.019
Performance status at HSCT
0 1 (reference) 1 (reference) 1 (reference) 1 (reference)
1–2 1.90 (0.77–4.68) 0.165 0.91 (0.26–3.12) 0.879 1.81 (0.81–4.04) 0.148 1.55 (0.53–4.53) 0.423
MRD status at HSCT
a
PCR negative 1 (reference) 1 (reference) 1 (reference) 1 (reference)
PCR positive 1.32 (0.52–3.35) 0.562 1.12 (0.33–3.83) 0.860 1.47 (0.64–3.36) 0.361 1.27 (0.46–3.48) 0.642
WBC at diagnosis ( 10
9/l)
o30 1 (reference) 1 (reference) 1 (reference) 1 (reference)
X30 1.50 (0.61–3.70) 0.376 1.44 (0.38–5.37) 0.590 1.71 (0.77–3.82) 0.191 1.67 (0.56–5.04) 0.360
CD 20 positivity
Negative 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Positive 0.56 (0.20–1.54) 0.260 0.30 (0.08–1.21) 0.091 0.74 (0.30–1.84) 0.519 0.68 (0.20–2.36) 0.548
Abbreviations: CI, conﬁdence of interval; DFS, disease-free survival; HSCT, hematopoietic stem cell transplantation; MRD, minimal residual disease; NE, not
estimated; OS, overall survival; WBC, white blood corpuscles.
aSubjects with unknown status were included in the analyses as dummy variable.
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gene translocation before allo-HSCT affect the prognosis of
patients after transplantation? An inspiring report from Kreil
et al.
20 veriﬁes a function of p40
ABL–BCR fusion protein in the
setting of allo-HSCT. They developed a DNA-based deletion
screen, and investigated 339 patients with chronic phase CML
Table 3. Uni- and multivariate competing risk regression analyses for relapse and NRM of 60 patients who received HSCT in their ﬁrst CR following
imatinib-based therapy
Characteristics Relapse NRM
Univariate Multivariate Univariate Multivariate
RR (95% CI) P RR (95% CI) P RR (95% CI) P RR (95% CI) P
Donor status
Related 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Unrelated 0.24 (0.03–1.92) 0.179 0.15 (0.01–2.51) 0.186 2.05 (0.74–5.69) 0.169 0.94 (0.24-3.63) 0.929
Age at HSCT (years)
–39 1 (reference) 1 (reference) 1 (reference) 1 (reference)
40– 0.68 (0.16–2.84) 0.600 0.07 (0.04–1.28) 0.073 1.29 (0.42–3.95) 0.634 2.47 (0.56-10.8) 0.229
Additional chromosome abnormality
a
No 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Yes 1.21 (0.15–9.59) 0.858 4.53 (0.28–73.4) 0.288 0.75 (0.22–2.61) 0.655 0.68 (0.12-3.90) 0.666
Stem-cell source
Bone marrow 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Peripheral blood 5.53 (1.06–29.0) 0.043 4.92 (0.17–144.0) 0.355 0.41 (0.10–1.73) 0.223 0.77 (0.11-5.23) 0.788
Cord blood 4.44 (0.68–29.2) 0.121 0.34 (0.01–10.1) 0.537 0.81 (0.16–4.09) 0.795 1.01 (0.10-9.89) 0.996
Conditioning regimen
Myeloablative 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Reduced intensity NE NE NE NE
BCR–ABL subtype
Minor 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Major 0.37 (0.05–2.90) 0.345 0.23 (0.05–1.15) 0.074 5.95 (2.06–17.2) 0.001 6.92 (2.09-22.9) 0.002
Performance status at HSCT
0 1 (reference) 1 (reference) 1 (reference) 1 (reference)
1–2 1.67 (0.45–6.20) 0.442 6.88 (0.96–49.1) 0.054 1.47 (0.52–4.14) 0.470 1.03 (0.24-4.46) 0.972
MRD status at HSCT
a
PCR negative 1 (reference) 1 (reference) 1 (reference) 1 (reference)
PCR positive 4.82 (1.20–19.4) 0.027 7.34 (0.54–99.4) 0.134 0.57 (0.15–2.13) 0.402 0.75 (0.15-3.84) 0.732
Abbreviations: CI, conﬁdence interval; CR, complete remission; HSCT, hematopoietic stem cell transplantation; MRD, minimal residual disease; NE, not
estimated; NRM, non-relapse mortality.
aSubjects with unknown status were included in the analyses as dummy variable.
Figure 2. OS and DFS, and cumulative incidence of relapse and NRM related to BCR–ABL subtypes in 60 patients with PhþALL who
underwent allo-HSCT in their ﬁrst CR following imatinib-based therapy. (a) OS, (b) DFS, (c) cumulative incidence of relapse and (d) cumulative
incidence of NRM.
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spanned the ABL–BCR junction and 38 were centromeric or
telomeric of the breakpoint. Patients with ABL–BCR junction-
spanning deletions (p40
ABL–BCR deﬁciency) had poorer survival,
compared with patients without deletions.
20 More interestingly,
this tendency was most distinctive in the setting of allo-HSCT
where bone marrow was replaced by normal stem cells from
healthy donor.
20 Deletions that did not span the ABL–BCR junction
were associated with improved survival, compared with patients
without deletions. From these, one could speculate that p40
ABL–BCR
has an important role on the stem-cell re-constitution after allo-
HSCT in patients with BCR–ABL-positive leukemia, and that, even
when the patient’s bone marrow was replaced by normal donor
stem cells, a deﬁciency of this protein induced by imatinib-
combined chemotherapy could contribute to the relatively high
incidence of graft failure (22%) in patients with major BCR–ABL
transcript as observed in our present study.
Investigation of transplant outcome of PhþALL patients who
expressed minor BCR–ABL transcript and der (9) deletion would be
helpful to evaluate clinical relevance of p96
ABL–BCR. However, to
our knowledge, there is no report focusing on the BCR–ABL
subtypes and der (9) deletions in patients with PhþALL. In our
present study, three patients who had der (9) deletions were all
positive for minor BCR–ABL transcript and alive at the last known
date of follow-up. Further investigation for clinico-biological
effects of not only BCR–ABL but also ABL–BCR transcripts will be
needed to clarify the prognostic relevance of BCR–ABL subtypes
after allo-HSCT in patients with PhþALL.
We categorized two patients with both major and minor
BCR–ABL transcripts into the major BCR–ABL transcript group.
Several investigators who studied PhþALL with both BCR–ABL
transcripts have reported that the level of minor BCR–ABL
transcript was consistently low, such as only one transcript per
100 cells with major BCR–ABL transcript.
21 Fujimaki et al.
22 studied
four patients with PhþALL with both transcripts before and after
allo-HSCT, and reported that PCR negativity for minor BCR–ABL
was documented in all cases 1–2 months before PCR negativity for
major BCR–ABL. Taking these preceding studies into consideration,
we believe our categorization of the two patients would be
justiﬁed.
In the present study, negative MRD before HSCT resulted in
signiﬁcantly lower relapse rate after HSCT (Table 3). Some
investigators reported that MRD before HSCT served as a powerful
predictor of lower relapse rate and better DFS.
4,23,24 Therefore,
prospective monitoring of MRD may potentially identify patients
at risk of relapse, although the implications of different transcript
levels and increments require validation within each therapeutic
context or clinical study.
4 These issues highlight the need for the
standardization and harmonization of methodologies used for
BCR–ABL quantiﬁcation in PhþALL.
4 Employment of highly
sensitive methods such as nested PCR or of normalization by
total ABL transcripts may make clear the predictive value of MRD
analysis for the prognosis after HSCT.
25
To our knowledge, this is the ﬁrst report on the clinical impact
of the BCR–ABL subtypes on the outcomes of patients with Phþ
ALL after allo-HSCT, analyzing results of a substantial number of
patients with a sufﬁcient follow-up period. However, the strength
and limitations of our study need to be considered. The strength
lies in the relatively large sample size, if not sufﬁcient, and
relatively homogenous population, as all patients received a
uniform imatinib-combined chemotherapy regimen (JALSG Phþ
ALL202)
12 and underwent allo-HSCT in their ﬁrst CR. These facts
gave us a better estimation of the endpoints, and also added
statistical power to the analyses. Our limitations are the presence
of residual confounding factors, both known and unknown, and
insufﬁcient number of patients in each different prognostic factor.
Among the known factors, difference in transplantation
procedure, including pre-transplant conditioning regimens,
should be noted. In this study, conditioning regimens and GVHD
prophylaxis were determined by each institution. However, the
small number of patients per institution and the changes of the
conditioning regimens themselves within the same institution
inevitably rendered the analysis on these factors impossible.
We have no comparative clinico-biological data in patients with
PhþALL transplanted during the pre-imatinib era, and were
unable to evaluate whether BCR–ABL subtype has a prognostic
impact during that time. Further study should be undertaken to
evaluate the prognostic value of BCR–ABL subtypes both in pre-
and post imatinib eras.
The treatment strategy for PhþALL in the imatinib era,
especially for PhþALL with major BCR–ABL transcript, should be
reconsidered, and additionally, not only allo-HSCT but also second
generation tyrosine kinase inhibitors need to be incorporated.
Further study would be warranted to determine the clinical impact
of BCR–ABL transcripts on the outcome of allo-HSCT in this disease.
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Table 4. Patient charateristics according to BCR–ABL subtype in
patients with PhþALL who received HSCT in their ﬁrst CR
following imatinib-based therapy
Minor
BCR–ABL (%)
Major
BCR–ABL (%)
P
No. of transplantations 42 18
Median days from diagnosis
to HSCT (range)
149 (84–322) 193 (67–512) 0.090
Conditioning regimen 0.658
Myeloablative 37 (88) 17 (94)
Reduced intensity 5 (12) 1 (6)
MRD status before HSCT
(3 subjects unknown)
1.000
Positive 13 (32) 5 (29)
Negative 27 (68) 12 (70)
HCT-CI (7 subjects unknown) 0.400
0 24 (67) 12 (70)
1 8 (22) 5 (30)
2– 4 (11)
Cause of death
Leukemia relapse 4 (10) 2 (11) 1.000
Trasnplant related 5 (12) 8 (44) 0.013
Graft failure 1 (2) 4 (22)
Infection 1 (2) 2 (11)
cGVHD 1 (2) 1 (5)
BO 2 (5)
Others 1 (5)
Abbreviations: BO, bronchiolitis obliterans; CR, complete remission;
cGVHD, chronic graft-versus-host disease; HCT-CI, hematopoietic cell
transplantation (HCT)-speciﬁc comorbidity index; HSCT, hematopoietic
stem cell transplantation; MRD, minimal residual disease; PhþALL,
Philadelphia chromosome-positive acute lymphoblastic leukemia.
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